Allogeneic heart transplantation following xenogeneic bridging.
Xenografting seems to be a solution to bridge the time intervals when an essential allograft cannot be obtained. A subsequent allograft was never tried. Eight dogs (20-24 kg) of 2 years of age underwent right cervical heart transplantation. Donors were silver foxes (3-4 kg). The animals were treated by triple drug therapy consisting of cyclosporin A, methylprednisolone and azathioprine in clinical dosages. For control, six recipients received allogeneic heart transplantation (AHTP) and the identical immunosuppression. After rejection of the xenograft, a second allogeneic heart was anastomosed to the same right cervical vessels. Routine histology and immunohistology were performed. Thromboxane B2 and 6-keto-prostaglandin Fla were determined daily in peripheral blood. After final rejection sensitization of the recipient was controlled by haemagglutination tests. Survival times of the xenografts were 9.6 +/- 1.2. The subsequent hearts under the same therapy beat for 4.5 +/- 5.0 days. The average survival time of control hearts was 18 +/- 1.9 days. The five hyperacute second allografts showed signs of humoral rejection by absence of inflammation. The release of thromboxane B2 was different in hyperacute, accelerated or cellular rejection. In contrast to the long-functioning grafts, thromboxane B2 persisted during hyperacute rejection at a high level. However 6-keto-prostaglandin Fla showed no significant differences between long-time survivors and hyperacute rejecting hearts. After xenogeneic transplantation all recipients showed haemagglutinating titres between 1:4 and 1:16. Allogeneic grafts have different kinetics of rejection following xenogeneic heart transplantation (XHTP) compared with control hearts. Thromboxane B2 seems to be an important mediator in hyperacute rejection. This type of rejection is not associated with a change in 6-keto-prostaglandin Fla levels. These results indicate, that xenogeneic bridging under a common immunosuppressive regimen could lead to accelerated rejection of the following allograft. Under this condition clinical bridging is not advisable.